Eucrisa

New treatments on the horizonEmerging therapies are showing impressive efficacy and good tolerability, according to one dermatologist.
February Clinical Considerations for NPs, PasIn our February Clinical Considerations, we take a look at treatment options for a few common skin disorders.
FDA approves corticosteroid-sparing topical option for eczemaThe FDA announced it has approved Eucrisa (Anacor Pharmaceuticals, crisaborole) ointment to treat mild to moderate eczema in patients two-years-of-age and older.